The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...

Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.